Document |
Document Title |
WO/2008/015429A2 |
The invention provides a compound of the formula (1) or a salt, solvate or tautomer thereof, having PARP inhibitor activity. In formula (1), Q is CN or CONH2 and is attached at either position "a" or position "b" on the benzene ring; Y1 ...
|
WO/2008/006738A1 |
The invention relates to a novel electron transport material based on annelated aromatic electron-deficient compounds. Due to the accumulation of electron-deficient aromatic rings, radical anions can be very well stabilized in these syst...
|
WO/2008/003141A1 |
Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof; with the proviso that the compound is not Tran...
|
WO/2007/138075A1 |
The invention relates to an improved method for preparing 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, also commonly known as lamotrigine. The present invention also relates to a method for preparing the intermediate 2,3-dichlorobe...
|
WO/2007/116314A1 |
N-Phenyl-1,1,1 -trifluoromethanesulfonamide compounds of formula 1 a, formula 1 b or formula 1c useful for controlling endo- and/or ectoparasites in the environment are provided, together with methods of making the same and methods of us...
|
WO/2007/104144A1 |
There are provided compounds represented by formula (I): in which R1 is F, CI, -N(R5)2 or -CN and Q+ is selected among various organic cations that include an heterocyle. These compounds are useful as electrolytes, ionic liquids or molte...
|
WO/2007/103694A2 |
Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11...
|
WO/2007/069265A1 |
This invention discloses a process for the preparation of 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine of a formula (I), commonly known as Lamotrigine which comprises the step of reacting aminoguanidine bicarbonarte and 2,3- dichlor...
|
WO/2007/063934A1 |
Disclosed is a compound represented by the formula below or a pharmaceutically acceptable salt thereof: (1) wherein the ring A represents a heterocyclic ring; the ring B represents a carbocyclic ring or a heterocyclic ring; P1 and P2 ind...
|
WO/2007/039463A1 |
The present invention provides compounds of formula (I) where R1 to R4 are as defined herein which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further prov...
|
WO/2007/017114A1 |
The invention relates to substituted azathymidines and related compounds of formula (I), wherein X is N or CH, and R1, R2 and R3 are as described in the specification, processes for the preparation thereof, pharmaceutical compositions co...
|
WO/2007/011721A1 |
The present invention relates to compounds useful as inhibitors of KSP and methods for the treatment or prevention of cellular proliferative diseases.
|
WO/2006/131835A2 |
The invention relates to novel heterocyclic triazines which are useful as hypoxic selective cytotoxic agents that mediate and/or inhibit cell proliferation, for example, through the activity of protein kinases. The invention is further r...
|
WO/2006/119400A2 |
This invention relates to substituted dihydrotriazinones, triazinones and related compounds, compositions comprising such compounds and an agronomically acceptable carrier, and the use thereof as broad spectrum fungicides. This invention...
|
WO/2006/111662A2 |
The invention relates to triazine derivatives of general formula (I) in which R1 represents a heteroaryl group or aryl group; R2 represents a hydrogen atom or a group (C1-C4) alkyl; R3 represents a group -(CH2)n-NR4R5 in which n is equal...
|
WO/2006/104406A1 |
The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensit...
|
WO2006047372A9 |
Generally, the present invention relates to lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to ...
|
WO/2006/095337A2 |
A process, which comprises reacting melamine and cyanuric acid in an aqueous medium to form melamine cyanurate, removing the product slurry from the reaction vessel in the presence of a volatile base, spray drying said product slurry and...
|
WO/2006/092507A1 |
The invention concerns 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein: R1 and R2, identical or different, represent a branched or linear C1-C7 alkyl or alkenyl radical, a C1-C6 alkyl radical substituted by g...
|
WO/2006/085108A1 |
Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2, W, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compo...
|
WO/2006/085112A1 |
Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2 and W, are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds ...
|
WO/2006/083271A2 |
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...
|
WO/2006/063813A2 |
The invention relates to 3-arylalkyl-substituted and 3-heteroarylalkyl-substituted-1,2,4-triazin-5(2H)-ones, to a method for the production thereof, and to their use for producing medicaments for treating and/or preventing diseases, part...
|
WO/2006/063791A1 |
The invention relates to 3-benzylthio-1,2,4-triazine-5 (2H)-one of formula I, methods for the production thereof, and the use thereof for producing medicaments that are used for the treatment and/or prevention of diseases, especially chr...
|
WO/2006/063811A2 |
The invention relates to substituted 1,2,4-triazin-5(2H)-ones, to a method for the production thereof, and to their use for producing medicaments for treating and/or preventing diseases, particularly chronic inflammatory diseases, for ex...
|
WO/2006/063812A1 |
The invention relates to 3-cycloalkyl-1,2,4-triazin-5(2H)-ones, to a method for the production thereof, and to their use for producing medicaments for treating and/or preventing diseases, particularly chronic inflammatory diseases, for e...
|
WO/2006/047451A2 |
Generally, the present invention relates to lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to ...
|
WO/2006/044975A2 |
The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds m...
|
WO/2006/024034A1 |
Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.
|
WO/2006/015985A1 |
The present invention relates to HIV replication inhibitors of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein ring A and ring B represent phenyl...
|
WO/2006/007468A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making ...
|
WO/2006/003513A1 |
The present invention relates to methods of preparing compounds of formula (I), R7 is -CH2-C(R10R11)-OH, wherein R10 and R11 are independently selected from the group consisting of: hydrogen, phenyl, and (C1-C6)alkyl optionally substitut...
|
WO/2006/003500A1 |
The present invention relates to the methods for preparing compounds of the formula (I): or the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R10, and R11 have any of the values defined in the specification. The compound...
|
WO/2005/121108A1 |
The invention relates to the use of 5,6-diphenyl-1,2,4-triazinic compounds of general formula (I), wherein cycle penetrating bonds display an ortho, meta or para indifferent substitution position, identical or different R1 and R2 represe...
|
WO/2005/121128A1 |
The invention relates to 5,6-diphenyl-1,2,4-triazinic compounds of general formula (I), wherein identical or different R1, R2, R3 and R4 represent a hydrogen, fluoride, chloride or bromine atom, C1 to C12 linear or branched alkyl, C1 A C...
|
WO/2005/115992A1 |
This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variant...
|
WO/2005/108368A1 |
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzy...
|
WO/2005/082867A1 |
The present invention provides a simplified set of characteristics that can be used to select 1,2,4 benzotriazine 1,4 dioxide compounds (TPZ analogues) with therapeutic activity against hypoxic cells in human tumour xenografts, and to fu...
|
WO/2005/080354A1 |
The invention relates to 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formulae (I or II), in which in particular: R1 represents hydrogen, a linear or branched C1-C6 alkyl or alkoxy radical, a C5-C6 cycloalkyl radical, a phenyl...
|
WO/2005/072361A2 |
Compounds of Formula I and Formula II (wherein A, E, j, k, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, X, Y and Z are as defined herein) which are modulat...
|
WO/2005/068446A1 |
This invention pertains to labeling reagents, labeled analytes, including mixtures thereof, and fragment ions derived therefrom. This invention also pertains to methods for the production of labeling reagents, including N-substituted pip...
|
WO/2005/054199A1 |
Compounds of general formula (I), (II) (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associa...
|
WO/2005/053055A1 |
The invention relates to the improvement of phosphorescing organic electroluminescent devices wherein triazines, pyrimidines, pyridazines and pyrazines are preferably used as materials in the hole blocking layer.
|
WO/2005/051391A1 |
A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the formula IA a...
|
WO/2005/037257A2 |
The invention relates to medicinally used substances which specifically inhibit peptidases splitting ala-p-nitroanilide. The invention further relates to the use of at least one such substance or at least one pharmaceutical or cosmetic c...
|
WO/2005/035500A2 |
The invention provides a compound of formula (I) (where R1, R1’, R2, R3, X, Y, Z and n are disclosed herein) or a pharmaceutically acceptable salt thereof (s “Diaminoalkylene Compound”); pharmaceutical compositions comprising an ef...
|
WO/2005/025681A2 |
For manufacturing a personal golf putter there are provided a putting surface with at least one hole into which a golfer putts balls, an initial putter with which the golfer hits the balls so as to put the balls into the hole, sensors fo...
|
WO/2005/023204A2 |
Prodrugs of propofol, methods of making prodrugs of propofol, pharmaceutical compositions of prodrugs of propofol and methods of using prodrugs of propofol and pharmaceutical compositions thereof to treat or prevent diseases or disorders...
|
WO/2005/021536A2 |
The invention relates to new compounds of the general formula (I), which are strong DPP-IV enzyme inhibitors.
|
WO2004112793B1 |
A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA...
|